Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-674-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.78 million
Profitability
Miscellaneous
Employees294
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) issued its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.05. The biotechnology company had revenue of $19.94 million for the quarter, compared to the consensus estimate of $15.60 million. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
1 brokerages have issued twelve-month target prices for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 51.1% from the stock's current price. View Analyst Price Targets for Agenus.
What is the consensus analysts' recommendation for Agenus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.
Has Agenus been receiving favorable news coverage?
Media coverage about AGEN stock has been trending somewhat positive on Thursday, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Agenus.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of Agenus own?
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
- Dr. Jennifer Buell, Chief Operating Officer
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
- Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
- Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)
Who are Agenus' major shareholders?
Agenus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.75%), Millennium Management LLC (0.55%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%), California State Teachers Retirement System (0.12%) and Barclays PLC (0.05%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin and Karen Valentine. View Institutional Ownership Trends for Agenus.
Which institutional investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Barclays PLC, Alberta Investment Management Corp, Metropolitan Life Insurance Co NY and Alps Advisors Inc.. View Insider Buying and Selling for Agenus.
Which institutional investors are buying Agenus stock?
AGEN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Millennium Management LLC, California Public Employees Retirement System, Commonwealth Equity Services LLC, Virtu Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $3.97.
How big of a company is Agenus?
Agenus has a market capitalization of $545.32 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.
What is Agenus' official website?
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
